Market Cap (In SEK)
908.83 Million
Revenue (In SEK)
-
Net Income (In SEK)
-179.66 Million
Avg. Volume
30.75 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 33.0-91.7
- PE
- -3.07
- EPS
- -8.62
- Beta Value
- 0.842
- ISIN
- SE0009973563
- CUSIP
- -
- CIK
- -
- Shares
- 34295574.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Per Andersson Ph.D.
- Employee Count
- -
- Website
- https://www.xspraypharma.com
- Ipo Date
- 2017-09-28
- Details
- Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
More Stocks
-
AWX
-
0R0PBlackBerry Limited
0R0P
-
BRNHF
-
SWA
-
1873
-
2158Yidu Tech Inc.
2158
-
8331The Chiba Bank, Ltd.
8331
-
0ID1